Indegene Limited has filed its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The company submitted the mandatory certificate as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming adherence to dematerialization compliance requirements.

Regulatory Compliance Filing

The certificate, dated April 09, 2026, was signed by Company Secretary and Compliance Officer Srishti Ramesh Kaushik. The filing confirms that all details of securities dematerialized during the quarter have been properly furnished to both BSE Limited and National Stock Exchange of India Limited, where the company's shares are listed.

RTA Confirmation

MUFG Intime India Private Limited, serving as the company's registrar and transfer agent, provided supporting confirmation dated April 6, 2026. The RTA confirmed that all securities received from depository participants for dematerialization during the quarter were processed and confirmed to the depositories within prescribed timelines.

Key confirmations from the RTA include:

• Securities received for dematerialization were properly confirmed or rejected to depositories
• All security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners
• All processes were completed within prescribed regulatory timelines

Dematerialization Activity

The RTA specifically noted that no requests for rematerialization were received during the quarter ended March 31, 2026. This indicates that all securities transactions during the period involved dematerialization processes only, with no conversion back to physical certificate form.

Corporate Information

Indegene Limited operates from its registered office at Manyata Embassy Business Park in Bengaluru, Karnataka. The company maintains its listing on both BSE Limited under scrip code 544172 and National Stock Exchange under the trading symbol INDGN. This quarterly filing represents part of the company's ongoing regulatory compliance obligations as a publicly listed entity in the Indian capital markets.

Indegene Limited has announced the completion of a Trade and Asset Purchase Agreement between its subsidiary Indegene Healthcare UK Limited and Trilogy Writing and Consulting Limited on April 01, 2026. The transaction involves the acquisition of trade and business assets as a going concern, valued at GBP 1,90,679.

Transaction Details

The asset purchase agreement represents a strategic consolidation within the Indegene group structure. Key aspects of the transaction include:

Related Party Transaction

The transaction qualifies as a related party transaction since both entities operate under the same corporate umbrella. The buyer had previously acquired the entire issued share capital of the seller, as disclosed in an intimation filed on March 1, 2026. Both companies are indirectly wholly owned by Indegene Limited, ensuring complete group control over the transaction.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that the related party transaction has been conducted on an arm's length basis, ensuring compliance with regulatory requirements. No special rights such as director appointment rights, share subscription preferences, or capital structure restrictions are associated with this agreement.

Corporate Structure Impact

The asset purchase consolidates business operations within the Indegene group structure. With 100% shareholding in both entities, the transaction represents an internal reorganization that streamlines business assets under unified ownership. The agreement does not involve any share issuance or loan arrangements, maintaining the existing corporate framework while optimizing asset allocation within the group.